J&J Saves Xarelto; But Faces tough Label
This article was originally published in RPM Report
Executive Summary
J&J’s defense of its pending stroke prevention indication in atrial fibrillation for Xarelto at the September 8 FDA Cardio-Renal Advisory Committee is likely to go down in FDA lore as an example of a successful argument that saved an application, but not the product. The presentation may also be notable into the future for two slides on benefit/risk which address one of FDA’s new interests: patient preferred outcomes.
You may also be interested in...
FDA Lifts Cloud Over J&J’s Xarelto With ROCKET-AF Re-Analysis
Agency reaffirms safety and efficacy in atrial fibrillation patients despite use of faulty coagulation monitoring device in pivotal trial led by current FDA Commissioner Robert Califf when he was at Duke University.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.